



2024 Formulary Changes

Updated 03/2024

H2168_MBR20-137_C

Updated 03/2024
H2168_MBR20-137_C

Page 1 of 2

EFFECTIVE DATE: 05/01/2024

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier
LEVONORG-ETH ESTRAD-FE BISGLYC 0.1-0.02MG ORAL TABLET	

CHANGE TYPE

DELETION OF DRUG FROM FORMULARY

CHANGE REASON

NOT A PART D COVERED DRUG

EFFECTIVE DATE: 04/01/2024

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier
RISPERDAL CONSTA 37.5MG/2ML INTRAMUSC. VIAL	RISPERIDONE ER 37.5MG/2ML INTRAMUSC. VIAL-5
PROLENSA 0.07 % OPHTHALMIC DROPS	BROMFENAC SODIUM 0.07 % OPHTHALMIC DROPS-3
RISPERDAL CONSTA 12.5MG/2ML INTRAMUSC. VIAL	RISPERIDONE ER 12.5MG/2ML INTRAMUSC. VIAL-3
RISPERDAL CONSTA 50 MG/2 ML INTRAMUSC. VIAL	RISPERIDONE ER 50 MG/2 ML INTRAMUSC. VIAL-5
RISPERDAL CONSTA 25 MG/2 ML INTRAMUSC. VIAL	RISPERIDONE ER 25 MG/2 ML INTRAMUSC. VIAL-3

CHANGE TYPE

BRAND DELETION, ADD FRF GENERIC

CHANGE REASON

REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT

EFFECTIVE DATE: 02/01/2024

AFFECTED DRUG NAME / ALTERNATIVE DRUG(S) AND TIER(S)

Drug Name	Alternate Drugs and Tier
ALPHAGAN P 0.1 % OPHTHALMIC DROPS	BRIMONIDINE TARTRATE 0.1 % OPHTHALMIC DROPS-3
VOTRIENT 200 MG ORAL TABLET	PAZOPANIB HCL 200 MG ORAL TABLET-5

CHANGE TYPE

BRAND DELETION, ADD FRF GENERIC

CHANGE REASON

REMOVAL OF BRAND NAME DRUG FROM FORMULARY DUE TO ADDITION OF NEW GENERIC EQUIVALENT